Literature DB >> 16389294

Pharmacological properties, central nervous system effects, and potential therapeutic applications of atipamezole, a selective alpha2-adrenoceptor antagonist.

Antti Pertovaara1, Antti Haapalinna, Jouni Sirviö, Raimo Virtanen.   

Abstract

Atipamezole is an alpha2-adrenoceptor antagonist with an imidazole structure. Receptor binding studies indicate that its affinity for alpha2-adrenoceptors and its alpha2/alpha1 selectivity ratio are considerably higher than those of yohimbine, the prototype alpha2-adrenoceptor antagonist. Atipamezole is not selective for subtypes of alpha2-adrenoceptors. Unlike many other alpha2-adrenoceptor antagonists, it has negligible affinity for 5-HT1A and I2 binding sites. Atipamezole is rapidly absorbed and distributed from the periphery to the central nervous system. In humans, atipamezole at doses up to 30 mg/subject produced no cardiovascular or subjective side effects, while at a high dose (100 mg/subject) it produced subjective symptoms, such as motor restlessness, and an increase in blood pressure. Atipamezole rapidly reverses sedation/anesthesia induced by alpha2-adrenoceptor agonists. Due to this property, atipamezole is commonly used by veterinarians to awaken animals from sedation/anesthesia induced by alpha2-adrenoceptor agonists alone or in combination with various anesthetics. Atipamezole increased sexual activity in rats and monkeys. In animals with sustained nociception, atipamezole increased pain-related responses by blocking the noradrenergic feedback inhibition of pain. In tests assessing cognitive functions, atipamezole at low doses has beneficial effects on alertness, selective attention, planning, learning, and recall in experimental animals, but not necessarily on short-term working memory. At higher doses atipamezole impaired performance in tests of cognitive functions, probably due to noradrenergic overactivity. Recent experimental animal studies suggest that atipamezole might have beneficial effects in the recovery from brain damage and might potentiate the anti-Parkinsonian effects of dopaminergic drugs. In phase I studies atipamezole has been well tolerated by human subjects.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16389294      PMCID: PMC6741735          DOI: 10.1111/j.1527-3458.2005.tb00047.x

Source DB:  PubMed          Journal:  CNS Drug Rev        ISSN: 1080-563X


  67 in total

1.  Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats.

Authors:  A Haapalinna; E MacDonald; T Viitamaa; J S Salonen; J Sirviö; R Virtanen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1999-03       Impact factor: 3.000

2.  The effects of a specific alpha(2)-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats.

Authors:  A Haapalinna; J Sirviö; E MacDonald; R Virtanen; E Heinonen
Journal:  Eur J Pharmacol       Date:  2000-01-10       Impact factor: 4.432

Review 3.  RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors.

Authors:  R W Clarke; J Harris
Journal:  CNS Drug Rev       Date:  2002

4.  Differentially altered cerebral metabolism in ischemic rats by alpha2-adrenoceptor blockade and its relation to improved limb-placing reactions.

Authors:  Alexandra Barbelivien; Jukka Jolkkonen; Edita Rutkauskaite; Jouri Sirviö; Juhani Sivenius
Journal:  Neuropharmacology       Date:  2002-01       Impact factor: 5.250

5.  An alpha(2)-adrenergic antagonist, atipamezole, facilitates behavioral recovery after focal cerebral ischemia in rats.

Authors:  K Puurunen; J Jolkkonen; J Sirviö; A Haapalinna; J Sivenius
Journal:  Neuropharmacology       Date:  2001-03       Impact factor: 5.250

6.  Behavioral effects of the alpha(2)-adrenoceptor antagonist, atipamezole, after focal cerebral ischemia in rats.

Authors:  J Jolkkonen; K Puurunen; S Rantakömi; A Härkönen; A Haapalinna; J Sivenius
Journal:  Eur J Pharmacol       Date:  2000-07-21       Impact factor: 4.432

7.  Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum.

Authors:  Leonid Yavich; Jouni Sirviö; Antti Haapalinna; Aarne Ylinen; Pekka T Männistö
Journal:  Eur J Pharmacol       Date:  2003-02-21       Impact factor: 4.432

8.  Neurokinin-1 projection cells in the rat dorsal horn receive synaptic contacts from axons that possess alpha2C-adrenergic receptors.

Authors:  M Josune Olave; David J Maxwell
Journal:  J Neurosci       Date:  2003-07-30       Impact factor: 6.167

9.  The effects of alpha-2 adrenoceptor antagonist, atipamezole, on spatial learning in scopolamine-treated and aged rats.

Authors:  J Sirviö; P Riekkinen; E MacDonald; M Airaksinen; R Lammintausta; P J Riekkinen
Journal:  J Neural Transm Park Dis Dement Sect       Date:  1992

10.  Role of the lateral septal noradrenergic system in the elaboration of male sexual behavior in rats.

Authors:  Kamalesh Kumari Gulia; Velayudhan Mohan Kumar; Hruda Nanda Mallick
Journal:  Pharmacol Biochem Behav       Date:  2002-07       Impact factor: 3.533

View more
  27 in total

1.  Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access.

Authors:  Sunmee Wee; Chitra D Mandyam; Dusan M Lekic; George F Koob
Journal:  Eur Neuropsychopharmacol       Date:  2007-10-24       Impact factor: 4.600

2.  Comparison of Atipamezole with Yohimbine for Antagonism of Xylazine in Mice Anesthetized with Ketamine and Xylazine.

Authors:  Christopher F Janssen; Pauline Maiello; M Jerry Wright; Kara B Kracinovsky; Joseph T Newsome
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-03-01       Impact factor: 1.232

3.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

4.  The antinociceptive effect of milnacipran in the monosodium iodoacetate model of osteoarthritis pain and its relation to changes in descending inhibition.

Authors:  Liam J Burnham; Anthony H Dickenson
Journal:  J Pharmacol Exp Ther       Date:  2013-01-07       Impact factor: 4.030

Review 5.  Therapeutic approaches to epileptogenesis--hope on the horizon.

Authors:  Asla Pitkänen
Journal:  Epilepsia       Date:  2010-07       Impact factor: 5.864

6.  The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand.

Authors:  Lane K Bekar; Helen S Wei; Maiken Nedergaard
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-08       Impact factor: 6.200

7.  Noradrenergic receptor modulation influences the acoustic parameters of pro-social rat ultrasonic vocalizations.

Authors:  Laura M Grant; Kelsey J Barth; Cagla Muslu; Cynthia A Kelm-Nelson; Vaishali P Bakshi; Michelle R Ciucci
Journal:  Behav Neurosci       Date:  2018-07-09       Impact factor: 1.912

8.  Alpha2-adrenergic impact on hypothalamic magnocellular oxytocinergic neurons in long evans and brattleboro rats: effects of agonist and antagonists.

Authors:  Jana Bundzikova; Zdeno Pirnik; Dora Zelena; Jens D Mikkelsen; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2009-03-17       Impact factor: 5.046

Review 9.  Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2016-08       Impact factor: 5.749

10.  Antinociception by motor cortex stimulation in the neuropathic rat: does the locus coeruleus play a role?

Authors:  Hanna Viisanen; Antti Pertovaara
Journal:  Exp Brain Res       Date:  2009-10-14       Impact factor: 1.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.